| Multiple Sclerosis, Relapsing-Remitting
Kesimpta vs Tecfidera
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, relapsing-remitting.Deep comparison between: Kesimpta vs Tecfidera with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTecfidera has a higher rate of injection site reactions vs Kesimpta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tecfidera but not Kesimpta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kesimpta
Tecfidera
At A Glance
SC injection
Once monthly
Anti-CD20 monoclonal antibody
Oral
Twice daily
Nrf2 pathway activator
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome 20 mg SC injection at Weeks 0, 1, and 2 (loading doses), then 20 mg SC once monthly starting at Week 4.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Starting dose 120 mg twice a day orally for 7 days; maintenance dose 240 mg twice a day orally.
Contraindications
- Active HBV infection
- History of hypersensitivity to ofatumumab or life-threatening injection-related reaction to KESIMPTA, including anaphylaxis and angioedema
- Known hypersensitivity to dimethyl fumarate or any excipient of TECFIDERA
Adverse Reactions
Most common (>10%) upper respiratory tract infections, injection-related reactions (systemic), headache, injection-site reactions (local)
Serious infections, injection-related reactions and hypersensitivity reactions, reduction in immunoglobulins, liver injury
Postmarketing hypersensitivity reactions, liver injury
Most common (>=10%) Flushing, abdominal pain, diarrhea, nausea
Serious Anaphylaxis, angioedema, progressive multifocal leukoencephalopathy, herpes zoster and other serious opportunistic infections, lymphopenia, liver injury
Postmarketing Acute pancreatitis, gastrointestinal perforation, ulceration, obstruction, and hemorrhage, liver function abnormalities, herpes zoster infection, rhinorrhea, alopecia
Pharmacology
Ofatumumab is a recombinant human IgG1 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes, resulting in antibody-dependent cellular cytolysis and complement-mediated lysis; the precise mechanism in multiple sclerosis is unknown but is presumed to involve B-lymphocyte depletion.
Dimethyl fumarate (DMF) and its active metabolite monomethyl fumarate (MMF) activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway involved in the cellular response to oxidative stress; the mechanism by which DMF exerts its therapeutic effect in multiple sclerosis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kesimpta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Tecfidera
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Kesimpta
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Tecfidera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Kesimpta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Tecfidera
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KesimptaView full Kesimpta profile
TecfideraView full Tecfidera profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.